Truist Financial Corp Has $60.59 Million Stake in McKesson Corporation $MCK

Truist Financial Corp grew its stake in McKesson Corporation (NYSE:MCK) by 2.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 73,869 shares of the company’s stock after purchasing an additional 1,729 shares during the quarter. Truist Financial Corp’s holdings in McKesson were worth $60,594,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. Obsidian Personal Planning Solutions LLC grew its stake in McKesson by 2.9% in the third quarter. Obsidian Personal Planning Solutions LLC now owns 426 shares of the company’s stock valued at $346,000 after acquiring an additional 12 shares during the period. Berkshire Asset Management LLC PA grew its stake in McKesson by 4.6% in the third quarter. Berkshire Asset Management LLC PA now owns 294 shares of the company’s stock valued at $227,000 after acquiring an additional 13 shares during the period. Norden Group LLC grew its stake in McKesson by 4.3% in the fourth quarter. Norden Group LLC now owns 317 shares of the company’s stock valued at $260,000 after acquiring an additional 13 shares during the period. Wealthcare Advisory Partners LLC grew its stake in McKesson by 0.7% in the fourth quarter. Wealthcare Advisory Partners LLC now owns 1,873 shares of the company’s stock valued at $1,536,000 after acquiring an additional 13 shares during the period. Finally, Red Door Wealth Management LLC grew its stake in McKesson by 3.8% in the fourth quarter. Red Door Wealth Management LLC now owns 358 shares of the company’s stock valued at $293,000 after acquiring an additional 13 shares during the period. Institutional investors and hedge funds own 85.07% of the company’s stock.

McKesson Trading Down 0.7%

MCK stock opened at $808.15 on Tuesday. The stock has a 50-day moving average price of $894.86 and a two-hundred day moving average price of $860.34. McKesson Corporation has a 1 year low of $637.00 and a 1 year high of $999.00. The stock has a market cap of $98.99 billion, a PE ratio of 23.24, a price-to-earnings-growth ratio of 1.18 and a beta of 0.35.

McKesson (NYSE:MCK) last announced its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The business had revenue of $106.16 billion for the quarter, compared to analyst estimates of $105.98 billion. During the same quarter last year, the firm earned $8.03 EPS. McKesson’s revenue for the quarter was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, analysts forecast that McKesson Corporation will post 39.02 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Investors of record on Monday, June 1st will be issued a dividend of $0.82 per share. The ex-dividend date is Monday, June 1st. This represents a $3.28 annualized dividend and a yield of 0.4%. McKesson’s dividend payout ratio is presently 9.43%.

Analyst Ratings Changes

MCK has been the subject of a number of research analyst reports. Wells Fargo & Company boosted their target price on McKesson from $914.00 to $925.00 and gave the company an “equal weight” rating in a research note on Thursday, February 5th. Raymond James Financial set a $970.00 target price on shares of McKesson in a report on Thursday, March 5th. Morgan Stanley restated an “overweight” rating and set a $966.00 target price on shares of McKesson in a report on Thursday, January 29th. Robert W. Baird set a $968.00 target price on shares of McKesson in a report on Wednesday, January 14th. Finally, William Blair initiated coverage on shares of McKesson in a report on Tuesday, April 28th. They set an “outperform” rating on the stock. Fourteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, McKesson presently has a consensus rating of “Moderate Buy” and an average price target of $972.27.

Insider Buying and Selling at McKesson

In related news, EVP Michele Lau sold 2,725 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the completion of the transaction, the executive vice president owned 3,247 shares in the company, valued at approximately $3,214,530. This represents a 45.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Leann B. Smith sold 190 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total transaction of $179,550.00. Following the transaction, the executive vice president owned 2,989 shares of the company’s stock, valued at $2,824,605. The trade was a 5.98% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 3,592 shares of company stock worth $3,518,555. Company insiders own 0.08% of the company’s stock.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.